Thus, CCAT2 plays a pivotal role in the tumor–stroma immune interplay within the tumor microenvironment, holding potential as a diagnostic and prognostic biomarker for CRC treatment while also offering insights into other cancer contexts [101,102]. The gene discussed is CCAT2; the disease is neoplasm.